FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024972915> ?p ?o ?g. }

• W2024972915 endingPage "514" @default.
• W2024972915 startingPage "504" @default.
• W2024972915 abstract "'Double-hit lymphomas' (DHL), defined by concurrent MYC and BCL2 (or, alternatively, BCL6) rearrangements, have a very poor outcome compared to standard-risk, diffuse large B-cell lymphomas (DLBCL). Consequently, dose-intensive (DI) therapies and/or consolidation with high-dose therapy and transplant have been explored in DHL, although benefit has been debated. This meta-analysis compared survival outcomes in DHL patients receiving dose-escalated regimens [DI: R-Hyper-CVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone) or R-CODOX-M/IVAC (rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, high dose cytarabine); or intermediate-dose: R-EPOCH (rituximab, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone)] versus standard-dose regimens (R-CHOP; rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in the first-line setting. Data were synthesized to estimate hazard ratios of dose-escalated treatments versus R-CHOP using a Weibull proportional hazards model within a Bayesian meta-analysis framework. Eleven studies examining 394 patients were included. Patients were treated with either front-line R-CHOP (n = 180), R-EPOCH (n = 91), or R-Hyper-CVAD/rituximab, methotrexate, cytarabine (R-M/C), R-CODOX-M/R-IVAC (DI) (n = 123). Our meta-analysis revealed that median progression-free survival (n = 350) for the R-CHOP, R-EPOCH and DI groups was 12·1, 22·2, and 18·9 months, respectively. First-line treatment with R-EPOCH significantly reduced the risk of a progression compared with R-CHOP (relative risk reduction of 34%; P = 0·032); however, overall survival (n = 374) was not significantly different across treatment approaches. A subset of patients might benefit from intensive induction with/without transplant. Further investigation into the role of transplant and novel therapy combinations is necessary." @default.
• W2024972915 created "2016-06-24" @default.
• W2024972915 creator A5001746827 @default.
• W2024972915 creator A5005058090 @default.
• W2024972915 creator A5013717203 @default.
• W2024972915 creator A5015896987 @default.
• W2024972915 creator A5023416353 @default.
• W2024972915 creator A5040808358 @default.
• W2024972915 creator A5042844727 @default.
• W2024972915 creator A5070363076 @default.
• W2024972915 creator A5080630441 @default.
• W2024972915 creator A5083072418 @default.
• W2024972915 creator A5086926245 @default.
• W2024972915 creator A5088286702 @default.
• W2024972915 creator A5089882481 @default.
• W2024972915 date "2015-04-24" @default.
• W2024972915 modified "2023-10-14" @default.
• W2024972915 title "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis" @default.
• W2024972915 cites W1502170811 @default.
• W2024972915 cites W1543770336 @default.
• W2024972915 cites W1598602811 @default.
• W2024972915 cites W1733056941 @default.
• W2024972915 cites W190208491 @default.
• W2024972915 cites W1912693401 @default.
• W2024972915 cites W1944683977 @default.
• W2024972915 cites W1971815003 @default.
• W2024972915 cites W1973001092 @default.
• W2024972915 cites W1978932947 @default.
• W2024972915 cites W1980920506 @default.
• W2024972915 cites W1996326223 @default.
• W2024972915 cites W1997677712 @default.
• W2024972915 cites W2002106466 @default.
• W2024972915 cites W2018071905 @default.
• W2024972915 cites W2028850684 @default.
• W2024972915 cites W2043622833 @default.
• W2024972915 cites W2057765075 @default.
• W2024972915 cites W2077482922 @default.
• W2024972915 cites W2113144077 @default.
• W2024972915 cites W2120415962 @default.
• W2024972915 cites W2139204503 @default.
• W2024972915 cites W2153944703 @default.
• W2024972915 cites W2159862107 @default.
• W2024972915 cites W2167571754 @default.
• W2024972915 cites W2167837696 @default.
• W2024972915 cites W2266142448 @default.
• W2024972915 cites W2470814946 @default.
• W2024972915 cites W2558563687 @default.
• W2024972915 cites W4214512856 @default.
• W2024972915 cites W4361866689 @default.
• W2024972915 cites W653751874 @default.
• W2024972915 cites W838883454 @default.
• W2024972915 doi "https://doi.org/10.1111/bjh.13463" @default.
• W2024972915 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25907897" @default.
• W2024972915 hasPublicationYear "2015" @default.
• W2024972915 type Work @default.
• W2024972915 sameAs 2024972915 @default.
• W2024972915 citedByCount "132" @default.
• W2024972915 countsByYear W20249729152014 @default.
• W2024972915 countsByYear W20249729152015 @default.
• W2024972915 countsByYear W20249729152016 @default.
• W2024972915 countsByYear W20249729152017 @default.
• W2024972915 countsByYear W20249729152018 @default.
• W2024972915 countsByYear W20249729152019 @default.
• W2024972915 countsByYear W20249729152020 @default.
• W2024972915 countsByYear W20249729152021 @default.
• W2024972915 countsByYear W20249729152022 @default.
• W2024972915 countsByYear W20249729152023 @default.
• W2024972915 crossrefType "journal-article" @default.
• W2024972915 hasAuthorship W2024972915A5001746827 @default.
• W2024972915 hasAuthorship W2024972915A5005058090 @default.
• W2024972915 hasAuthorship W2024972915A5013717203 @default.
• W2024972915 hasAuthorship W2024972915A5015896987 @default.
• W2024972915 hasAuthorship W2024972915A5023416353 @default.
• W2024972915 hasAuthorship W2024972915A5040808358 @default.
• W2024972915 hasAuthorship W2024972915A5042844727 @default.
• W2024972915 hasAuthorship W2024972915A5070363076 @default.
• W2024972915 hasAuthorship W2024972915A5080630441 @default.
• W2024972915 hasAuthorship W2024972915A5083072418 @default.
• W2024972915 hasAuthorship W2024972915A5086926245 @default.
• W2024972915 hasAuthorship W2024972915A5088286702 @default.
• W2024972915 hasAuthorship W2024972915A5089882481 @default.
• W2024972915 hasBestOaLocation W20249729151 @default.
• W2024972915 hasConcept C121332964 @default.
• W2024972915 hasConcept C126322002 @default.
• W2024972915 hasConcept C1276947 @default.
• W2024972915 hasConcept C143998085 @default.
• W2024972915 hasConcept C150846664 @default.
• W2024972915 hasConcept C207103383 @default.
• W2024972915 hasConcept C2776694085 @default.
• W2024972915 hasConcept C2776755627 @default.
• W2024972915 hasConcept C2778041864 @default.
• W2024972915 hasConcept C2778119113 @default.
• W2024972915 hasConcept C2779338263 @default.
• W2024972915 hasConcept C2779429289 @default.
• W2024972915 hasConcept C2780317896 @default.
• W2024972915 hasConcept C2780653079 @default.
• W2024972915 hasConcept C2780739268 @default.
• W2024972915 hasConcept C44249647 @default.

• next